Home Evaluation of a JAK2 V617F quantitative PCR to monitor residual disease post-allogeneic hematopoietic stem cell transplantation for myeloproliferative neoplasms
Article
Licensed
Unlicensed Requires Authentication

Evaluation of a JAK2 V617F quantitative PCR to monitor residual disease post-allogeneic hematopoietic stem cell transplantation for myeloproliferative neoplasms

  • Karl Haslam EMAIL logo , Karen M. Molloy , Eibhlin Conneally and Stephen E. Langabeer
Published/Copyright: October 12, 2013

Received: 2013-09-13
Accepted: 2013-09-19
Published Online: 2013-10-12
Published in Print: 2014-03-01

©2014 by Walter de Gruyter Berlin Boston

Articles in the same Issue

  1. Masthead
  2. Masthead
  3. Editorial
  4. Point of care testing: evolving scenarios and innovative perspectives
  5. Review
  6. Point-of-care testing: where is the evidence? A systematic survey
  7. Mini Review
  8. Vulnerability of point-of-care test reagents and instruments to environmental stresses: implications for health professionals and developers
  9. Opinion Paper
  10. Twenty-five years of idiopathic calcium nephrolithiasis: has anything changed?
  11. Genetics and Molecular Diagnostics
  12. Optimizing the purification and analysis of miRNAs from urinary exosomes
  13. General Clinical Chemistry and Laboratory Medicine
  14. Extensive study of human insulin immunoassays: promises and pitfalls for insulin analogue detection and quantification
  15. Absorptive chemistry based extraction for LC-MS/MS analysis of small molecule analytes from biological fluids – an application for 25-hydroxyvitamin D
  16. Evaluation of 3-epi-25-hydroxyvitamin D3 cross-reactivity in the Roche Elecsys Vitamin D Total protein binding assay
  17. Quantification of linezolid in serum by LC-MS/MS using semi-automated sample preparation and isotope dilution internal standardization
  18. Comparison of two immunoassays for measurement of faecal calprotectin in detection of inflammatory bowel disease: (pre)-analytical and diagnostic performance characteristics
  19. Reference Values and Biological Variations
  20. Reference change values to assess changes in concentrations of biomarkers of exposure in individuals participating in a cigarette-switching study
  21. Reference values of fetal serum β2-microglobulin in the Chinese: evaluation of its clinical usefulness
  22. Cancer Diagnostics
  23. Gut neuroendocrine tumor blood qPCR fingerprint assay: characteristics and reproducibility
  24. Androgen deprivation decreases prostate specific antigen in the absence of tumor: implications for interpretation of PSA results
  25. Radioimmunoassay of free plasma metanephrines for the diagnosis of catecholamine-producing tumors
  26. Infectious Diseases
  27. Plasma endothelial cell-specific molecule-1 (ESM-1) in management of community-acquired pneumonia
  28. A soluble form of the macrophage-related mannose receptor (MR/CD206) is present in human serum and elevated in critical illness
  29. Letters to the Editor
  30. Evaluation of a JAK2 V617F quantitative PCR to monitor residual disease post-allogeneic hematopoietic stem cell transplantation for myeloproliferative neoplasms
  31. Is magnetic resonance imaging really innocent?
  32. Clinical sample stability and measurement uncertainty
  33. A specific and sensitive activated partial thromboplastin time (APTT)-based factor VIII inhibitor screening assay
  34. Evaluating the inappropriateness of repeated laboratory testing in a teaching hospital of South Italy
  35. Could kidney glomerular filtration impairment represent the “Achilles heel” of HE4 serum marker? A possible further implication
Downloaded on 7.10.2025 from https://www.degruyterbrill.com/document/doi/10.1515/cclm-2013-0768/html
Scroll to top button